{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T08:11:59Z","timestamp":1793261519355,"version":"4.5.0"},"reference-count":128,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,13]],"date-time":"2022-06-13T00:00:00Z","timestamp":1655078400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Basic to Translational Science"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.jacbts.2022.05.010","type":"journal-article","created":{"date-parts":[[2022,9,7]],"date-time":"2022-09-07T18:10:17Z","timestamp":1662574217000},"page":"88-105","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":123,"title":["Neprilysin Inhibitors in Heart\u00a0Failure"],"prefix":"10.1016","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6362-0253","authenticated-orcid":false,"given":"Biykem","family":"Bozkurt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajith P.","family":"Nair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arunima","family":"Misra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire Z.","family":"Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamal H.","family":"Mahar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Savitri","family":"Fedson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.jacbts.2022.05.010_bib1","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1042\/bj1370477","article-title":"The purification and specificity of a neutral endopeptidase from rabbit kidney brush border","volume":"137","author":"Kerr","year":"1974","journal-title":"Biochem J"},{"issue":"5687","key":"10.1016\/j.jacbts.2022.05.010_bib2","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/276523a0","article-title":"High-affinity enkephalin-degrading peptidase in brain is increased after morphine","volume":"276","author":"Malfroy","year":"1978","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.jacbts.2022.05.010_bib3","doi-asserted-by":"crossref","first-page":"3111","DOI":"10.1073\/pnas.80.10.3111","article-title":"Substance P and [Leu]enkephalin are hydrolyzed by an enzyme in pig caudate synaptic membranes that is identical with the endopeptidase of kidney microvilli","volume":"80","author":"Matsas","year":"1983","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"10.1016\/j.jacbts.2022.05.010_bib4","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1084\/jem.168.4.1247","article-title":"Common acute lymphocytic leukemia antigen is identical to neutral endopeptidase","volume":"168","author":"Letarte","year":"1988","journal-title":"J\u00a0Exp Med"},{"issue":"10","key":"10.1016\/j.jacbts.2022.05.010_bib5","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1136\/jclinpath-2015-202955","article-title":"CD10-positive mantle cell lymphoma: biologically distinct entity or an aberrant immunophenotype? Insight, through gene expression profile in a unique case series","volume":"68","author":"Akhter","year":"2015","journal-title":"J\u00a0Clin Pathol"},{"issue":"3","key":"10.1016\/j.jacbts.2022.05.010_bib6","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1038\/bjc.2014.289","article-title":"CD10 as a novel marker of therapeutic resistance and cancer stem cells in head and neck squamous cell carcinoma","volume":"111","author":"Fukusumi","year":"2014","journal-title":"Br J Cancer"},{"issue":"51","key":"10.1016\/j.jacbts.2022.05.010_bib7","doi-asserted-by":"crossref","first-page":"39819","DOI":"10.1074\/jbc.M110.161547","article-title":"Neprilysin is identical to skin fibroblast elastase: its role in skin aging and UV responses","volume":"285","author":"Morisaki","year":"2010","journal-title":"J\u00a0Biol Chem"},{"issue":"5","key":"10.1016\/j.jacbts.2022.05.010_bib8","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1096\/fasebj.11.5.9141502","article-title":"Mammalian membrane metallopeptidases: NEP, ECE, KELL, and PEX","volume":"11","author":"Turner","year":"1997","journal-title":"FASEB J"},{"issue":"1","key":"10.1016\/j.jacbts.2022.05.010_bib9","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S0031-6997(25)00449-1","article-title":"Neutral endopeptidase 24.11: structure, inhibition, and experimental and clinical pharmacology","volume":"45","author":"Roques","year":"1993","journal-title":"Pharmacol Rev"},{"issue":"7","key":"10.1016\/j.jacbts.2022.05.010_bib10","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.jacc.2014.11.048","article-title":"Soluble neprilysin is predictive of cardiovascular death and heart failure hospitalization in heart failure patients","volume":"65","author":"Bayes-Genis","year":"2015","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"11","key":"10.1016\/j.jacbts.2022.05.010_bib11","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.jacbts.2022.05.010_bib12","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/0024-3205(81)90370-2","article-title":"A\u00a0rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats","volume":"28","author":"de Bold","year":"1981","journal-title":"Life Sci"},{"issue":"4","key":"10.1016\/j.jacbts.2022.05.010_bib13","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/1071-9164(95)90007-1","article-title":"Alterations in metabolic clearance of atrial natriuretic peptides in heart failure: how do they relate to the resistance to atrial natriuretic peptides?","volume":"1","author":"Clerico","year":"1995","journal-title":"J\u00a0Card Fail"},{"issue":"4","key":"10.1016\/j.jacbts.2022.05.010_bib14","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S0953-6205(02)00033-X","article-title":"Endothelial dysfunction in chronic heart failure: clinical and therapeutic implications","volume":"13","author":"Adamopoulos","year":"2002","journal-title":"Eur J Intern Med"},{"issue":"6","key":"10.1016\/j.jacbts.2022.05.010_bib15","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.jacc.2016.04.060","article-title":"A\u00a0test in context: neprilysin: function, inhibition, and biomarker","volume":"68","author":"Bayes-Genis","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"11","key":"10.1016\/j.jacbts.2022.05.010_bib16","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1111\/j.1742-4658.2011.08082.x","article-title":"Natriuretic peptide metabolism, clearance and degradation","volume":"278","author":"Potter","year":"2011","journal-title":"FEBS J"},{"issue":"23","key":"10.1016\/j.jacbts.2022.05.010_bib17","doi-asserted-by":"crossref","first-page":"2701","DOI":"10.1016\/S0024-3205(02)01990-2","article-title":"Increased expression of renal neutral endopeptidase in severe heart failure","volume":"71","author":"Knecht","year":"2002","journal-title":"Life Sci"},{"issue":"6","key":"10.1016\/j.jacbts.2022.05.010_bib18","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1161\/01.RES.71.6.1501","article-title":"Effect of inhibition of endopeptidase 24.11 on responses to angiotensin II in human volunteers","volume":"71","author":"Richards","year":"1992","journal-title":"Circ Res"},{"issue":"23","key":"10.1016\/j.jacbts.2022.05.010_bib19","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1161\/01.CIR.97.23.2323","article-title":"Inhibition of neutral endopeptidase causes vasoconstriction of human resistance vessels in\u00a0vivo","volume":"97","author":"Ferro","year":"1998","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.jacbts.2022.05.010_bib20","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/ejhf.250","article-title":"Neprilysin inhibition to treat heart failure: a tale of science, serendipity, and second chances","volume":"17","author":"McMurray","year":"2015","journal-title":"Eur J Heart Fail"},{"issue":"8","key":"10.1016\/j.jacbts.2022.05.010_bib21","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1038\/nm0897-904","article-title":"The control of microvascular permeability and blood pressure by neutral endopeptidase","volume":"3","author":"Lu","year":"1997","journal-title":"Nat Med"},{"issue":"3","key":"10.1016\/j.jacbts.2022.05.010_bib22","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.peptides.2003.12.010","article-title":"Angiotensin converting enzyme (ACE) and neprilysin hydrolyze neuropeptides: a brief history, the beginning and follow-ups to early studies","volume":"25","author":"Skidgel","year":"2004","journal-title":"Peptides"},{"issue":"5","key":"10.1016\/j.jacbts.2022.05.010_bib23","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.119.005851","article-title":"Enkephalins and the opioid system of the heart","volume":"12","author":"Bozkurt","year":"2019","journal-title":"Circ Heart Fail"},{"issue":"5","key":"10.1016\/j.jacbts.2022.05.010_bib24","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.118.005544","article-title":"Proenkephalin, an opioid system surrogate, as a novel comprehensive renal marker in heart failure","volume":"12","author":"Emmens","year":"2019","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jacbts.2022.05.010_bib25","doi-asserted-by":"crossref","unstructured":"Alvarez-Perez B, Poras H, Maldonado R. The inhibition of enkephalin catabolism by dual enkephalinase inhibitor: a novel possible therapeutic approach for opioid use disorders. Br J Pharmacol. Published online August 11, 2021. https:\/\/doi.org\/10.1111\/bph.15656","DOI":"10.1111\/bph.15656"},{"issue":"1","key":"10.1016\/j.jacbts.2022.05.010_bib26","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.ajpath.2010.11.012","article-title":"Neprilysin-2 is an important beta-amyloid degrading enzyme","volume":"178","author":"Hafez","year":"2011","journal-title":"Am J Pathol"},{"issue":"4","key":"10.1016\/j.jacbts.2022.05.010_bib27","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.3233\/JAD-142463","article-title":"Neprilysin deficiency alters the neuropathological and behavioral phenotype in the 5XFAD mouse model of Alzheimer's disease","volume":"44","author":"Huttenrauch","year":"2015","journal-title":"J\u00a0Alzheimers Dis"},{"issue":"3","key":"10.1016\/j.jacbts.2022.05.010_bib28","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1007\/s12031-010-9460-8","article-title":"Intranasal phosphoramidon increases beta-amyloid levels in wild-type and NEP\/NEP2-deficient mice","volume":"43","author":"Hanson","year":"2011","journal-title":"J\u00a0Mol Neurosci"},{"issue":"15","key":"10.1016\/j.jacbts.2022.05.010_bib29","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1093\/eurheartj\/ehv015","article-title":"Neprilysin, cardiovascular, and Alzheimer\u2019s diseases: the therapeutic split?","volume":"36","author":"Vodovar","year":"2015","journal-title":"Eur Heart J"},{"issue":"1-2","key":"10.1016\/j.jacbts.2022.05.010_bib30","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.jns.2014.07.064","article-title":"Meta-analysis of the association between two neprilysin gene polymorphisms and Alzheimer\u2019s disease","volume":"346","author":"Guo","year":"2014","journal-title":"J\u00a0Neurol Sci"},{"issue":"4","key":"10.1016\/j.jacbts.2022.05.010_bib31","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1523\/JNEUROSCI.4220-08.2009","article-title":"Neuropeptide Y fragments derived from neprilysin processing are neuroprotective in a transgenic model of Alzheimer\u2019s disease","volume":"29","author":"Rose","year":"2009","journal-title":"J\u00a0Neurosci"},{"issue":"4","key":"10.1016\/j.jacbts.2022.05.010_bib32","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.preteyeres.2011.02.004","article-title":"Parallel findings in age-related macular degeneration and Alzheimer\u2019s disease","volume":"30","author":"Ohno-Matsui","year":"2011","journal-title":"Prog Retin Eye Res"},{"key":"10.1016\/j.jacbts.2022.05.010_bib33","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.exer.2015.06.027","article-title":"Reduction of amyloid-beta levels in mouse eye tissues by intra-vitreally delivered neprilysin","volume":"138","author":"Parthasarathy","year":"2015","journal-title":"Exp Eye Res"},{"issue":"9","key":"10.1016\/j.jacbts.2022.05.010_bib34","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0012793","article-title":"New function for an old enzyme: NEP deficient mice develop late-onset obesity","volume":"5","author":"Becker","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.jacbts.2022.05.010_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.mad.2020.111363","article-title":"Neprilysin expression and functions in development, ageing and disease","volume":"192","author":"Nalivaeva","year":"2020","journal-title":"Mech Ageing Dev"},{"issue":"2","key":"10.1016\/j.jacbts.2022.05.010_bib36","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1562\/0031-8655(2001)074<0283:TROESB>2.0.CO;2","article-title":"The role of elastases secreted by fibroblasts in wrinkle formation: implication through selective inhibition of elastase activity","volume":"74","author":"Tsuji","year":"2001","journal-title":"Photochem Photobiol"},{"issue":"8663","key":"10.1016\/j.jacbts.2022.05.010_bib37","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/S0140-6736(89)90714-9","article-title":"Effects of UK 69 578: a novel atriopeptidase inhibitor","volume":"2","author":"Northridge","year":"1989","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.jacbts.2022.05.010_bib38","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1161\/01.CIR.86.4.1089","article-title":"Neurohormonal inhibition and hemodynamic unloading during prolonged inhibition of ANF degradation in patients with severe chronic heart failure","volume":"86","author":"Munzel","year":"1992","journal-title":"Circulation"},{"issue":"19","key":"10.1016\/j.jacbts.2022.05.010_bib39","doi-asserted-by":"crossref","first-page":"7580","DOI":"10.1073\/pnas.86.19.7580","article-title":"Protection of atrial natriuretic factor against degradation: diuretic and natriuretic responses after in\u00a0vivo inhibition of enkephalinase (EC 3.4.24.11) by acetorphan","volume":"86","author":"Gros","year":"1989","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"8681","key":"10.1016\/j.jacbts.2022.05.010_bib40","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/0140-6736(90)90595-V","article-title":"Effect of sinorphan on plasma atrial natriuretic factor in congestive heart failure","volume":"335","author":"Kahn","year":"1990","journal-title":"Lancet"},{"issue":"6 pt 1","key":"10.1016\/j.jacbts.2022.05.010_bib41","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1016\/S0002-8703(99)70081-5","article-title":"A\u00a0randomized trial of ecadotril versus placebo in patients with mild to moderate heart failure: the U.S. ecadotril pilot safety study","volume":"138","author":"O\u2019Connor","year":"1999","journal-title":"Am Heart J"},{"issue":"9116","key":"10.1016\/j.jacbts.2022.05.010_bib42","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1016\/S0140-6736(05)77712-6","article-title":"Lack of efficacy of neutral endopeptidase inhibitor ecadotril in heart failure. The International Ecadotril Multi-Centre Dose-Ranging Study Investigators","volume":"351","author":"Cleland","year":"1998","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.jacbts.2022.05.010_bib43","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1517\/13543784.8.1.79","article-title":"The endopeptidase inhibitor, candoxatril, and its therapeutic potential in the treatment of chronic cardiac failure in man","volume":"8","author":"McDowell","year":"1999","journal-title":"Expert Opin Investig Drugs"},{"issue":"10","key":"10.1016\/j.jacbts.2022.05.010_bib44","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1080\/004982597240046","article-title":"Formation and pharmacokinetics of the active drug candoxatrilat in mouse, rat, rabbit, dog and man following administration of the prodrug candoxatril","volume":"27","author":"Kaye","year":"1997","journal-title":"Xenobiotica"},{"issue":"1","key":"10.1016\/j.jacbts.2022.05.010_bib45","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S1388-9842(98)00003-8","article-title":"Placebo-controlled comparison of candoxatril, an orally active neutral endopeptidase inhibitor, and captopril in patients with chronic heart failure","volume":"1","author":"Northridge","year":"1999","journal-title":"Eur J Heart Fail"},{"issue":"12","key":"10.1016\/j.jacbts.2022.05.010_bib46","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1053\/euhj.1998.1201","article-title":"Candoxatril improves exercise capacity in patients with chronic heart failure receiving angiotensin converting enzyme inhibition","volume":"19","author":"Newby","year":"1998","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.jacbts.2022.05.010_bib47","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1159\/000177059","article-title":"Effects of renal neutral endopeptidase inhibition on sodium excretion, renal hemodynamics and neurohormonal activation in patients with congestive heart failure","volume":"87","author":"Kimmelstiel","year":"1996","journal-title":"Cardiology"},{"issue":"6 pt 1","key":"10.1016\/j.jacbts.2022.05.010_bib48","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/S0002-8703(99)70082-7","article-title":"Comparison of the short-term effects of candoxatril, an orally active neutral endopeptidase inhibitor, and frusemide in the treatment of patients with chronic heart failure","volume":"138","author":"Northridge","year":"1999","journal-title":"Am Heart J"},{"issue":"6","key":"10.1016\/j.jacbts.2022.05.010_bib49","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1016\/S0735-1097(99)00435-0","article-title":"Hemodynamic and neuroendocrine effects for candoxatril and frusemide in mild stable chronic heart failure","volume":"34","author":"Westheim","year":"1999","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"4","key":"10.1016\/j.jacbts.2022.05.010_bib50","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1136\/hrt.68.10.387","article-title":"Increased circulating atrial natriuretic factor concentrations in patients with chronic heart failure after inhibition of neutral endopeptidase: effects on diastolic function","volume":"68","author":"Northridge","year":"1992","journal-title":"Br Heart J"},{"issue":"3-4","key":"10.1016\/j.jacbts.2022.05.010_bib51","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s002280050196","article-title":"Neutral endopeptidase 24.11 inhibition may not exhibit beneficial haemodynamic effects in patients with congestive heart failure","volume":"51","author":"Kentsch","year":"1996","journal-title":"Eur J Clin Pharmacol"},{"issue":"6 pt 2","key":"10.1016\/j.jacbts.2022.05.010_bib52","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1161\/01.HYP.26.6.1160","article-title":"Comparison of candoxatril and atrial natriuretic factor in healthy men. Effects on hemodynamics, sympathetic activity, heart rate variability, and endothelin","volume":"26","author":"Ando","year":"1995","journal-title":"Hypertension"},{"issue":"15","key":"10.1016\/j.jacbts.2022.05.010_bib53","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1161\/hc4001.097191","article-title":"Vasopeptidase inhibitors: a new therapeutic concept in cardiovascular disease?","volume":"104","author":"Corti","year":"2001","journal-title":"Circulation"},{"issue":"7","key":"10.1016\/j.jacbts.2022.05.010_bib54","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1097\/00004872-199507000-00012","article-title":"Neutral endopeptidase versus angiotensin converting enzyme inhibition in essential hypertension","volume":"13","author":"Favrat","year":"1995","journal-title":"J\u00a0Hypertens"},{"issue":"9230","key":"10.1016\/j.jacbts.2022.05.010_bib55","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/S0140-6736(00)02602-7","article-title":"Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial","volume":"356","author":"Rouleau","year":"2000","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.jacbts.2022.05.010_bib56","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1161\/01.CIR.0000029801.86489.50","article-title":"Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE)","volume":"106","author":"Packer","year":"2002","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.jacbts.2022.05.010_bib57","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.amjhyper.2003.09.014","article-title":"Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial","volume":"17","author":"Kostis","year":"2004","journal-title":"Am J Hypertens"},{"issue":"6","key":"10.1016\/j.jacbts.2022.05.010_bib58","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1056\/NEJMoa1812851","article-title":"Angiotensin-neprilysin inhibition in acute decompensated heart failure","volume":"380","author":"Velazquez","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.jacbts.2022.05.010_bib59","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1001\/jamacardio.2021.4567","article-title":"Effect of treatment with sacubitril\/valsartan in patients with advanced heart failure and reduced ejection fraction: a randomized clinical trial","volume":"7","author":"Mann","year":"2022","journal-title":"JAMA Cardiol"},{"issue":"17","key":"10.1016\/j.jacbts.2022.05.010_bib60","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","article-title":"Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction","volume":"381","author":"Solomon","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"20","key":"10.1016\/j.jacbts.2022.05.010_bib61","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1056\/NEJMoa2104508","article-title":"Angiotensin receptor-neprilysin inhibition in acute myocardial infarction","volume":"385","author":"Pfeffer","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1016\/j.jacbts.2022.05.010_bib62","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1002\/ejhf.548","article-title":"Initiating sacubitril\/valsartan (LCZ696) in heart failure: results of TITRATION, a double-blind, randomized comparison of two uptitration regimens","volume":"18","author":"Senni","year":"2016","journal-title":"Eur J Heart Fail"},{"issue":"6","key":"10.1016\/j.jacbts.2022.05.010_bib63","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.jacc.2017.04.025","volume":"70","author":"Yancy","year":"2017","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"8","key":"10.1016\/j.jacbts.2022.05.010_bib64","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1002\/ejhf.1498","article-title":"Initiation of sacubitril\/valsartan in haemodynamically stabilised heart failure patients in hospital or early after discharge: primary results of the randomised TRANSITION study","volume":"21","author":"Wachter","year":"2019","journal-title":"Eur J Heart Fail"},{"issue":"9851","key":"10.1016\/j.jacbts.2022.05.010_bib65","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1016\/S0140-6736(12)61227-6","article-title":"The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial","volume":"380","author":"Solomon","year":"2012","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.jacbts.2022.05.010_bib66","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1001\/jama.2019.12821","article-title":"Association of change in N-terminal pro-B-type natriuretic peptide following initiation of sacubitril-valsartan treatment with cardiac structure and function in patients with heart failure with reduced ejection fraction","volume":"322","author":"Januzzi","year":"2019","journal-title":"JAMA"},{"issue":"11","key":"10.1016\/j.jacbts.2022.05.010_bib67","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1001\/jama.2019.12843","article-title":"Effect of sacubitril-valsartan vs enalapril on aortic stiffness in patients with heart failure and reduced ejection fraction: a randomized clinical trial","volume":"322","author":"Desai","year":"2019","journal-title":"JAMA"},{"issue":"19","key":"10.1016\/j.jacbts.2022.05.010_bib68","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1001\/jama.2021.18463","article-title":"Effect of sacubitril\/valsartan vs standard medical therapies on plasma NT-proBNP concentration and submaximal exercise capacity in patients with heart failure and preserved ejection fraction: the PARALLAX randomized clinical trial","volume":"326","author":"Pieske","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.jacbts.2022.05.010_bib69","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ahj.2017.07.006","article-title":"Design for the sacubitril\/valsartan (LCZ696) compared with enalapril study of pediatric patients with heart failure due to systemic left ventricle systolic dysfunction (PANORAMA-HF study)","volume":"193","author":"Shaddy","year":"2017","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacbts.2022.05.010_bib70","unstructured":"U.S. Food and Drug Administration. Entresto prescribing information. 2019. Accessed March 13, 2022. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/207620s013lbl.pdf"},{"issue":"2","key":"10.1016\/j.jacbts.2022.05.010_bib71","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1002\/ejhf.656","article-title":"Chronic heart failure as a state of reduced effectiveness of the natriuretic peptide system: implications for therapy","volume":"19","author":"Diez","year":"2017","journal-title":"Eur J Heart Fail"},{"issue":"1","key":"10.1016\/j.jacbts.2022.05.010_bib72","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1161\/01.CIR.87.1.70","article-title":"Possibility of downregulation of atrial natriuretic peptide receptor coupled to guanylate cyclase in peripheral vascular beds of patients with chronic severe heart failure","volume":"87","author":"Tsutamoto","year":"1993","journal-title":"Circulation"},{"issue":"8","key":"10.1016\/j.jacbts.2022.05.010_bib73","first-page":"629","article-title":"Elevated plasma B-type natriuretic peptide concentrations directly inhibit circulating neprilysin activity in heart failure","volume":"3","author":"Vodovar","year":"2015","journal-title":"J\u00a0Am Coll Cardiol HF"},{"issue":"5","key":"10.1016\/j.jacbts.2022.05.010_bib74","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1172\/JCI112723","article-title":"Atrial natriuretic factor in normal subjects and heart failure patients. Plasma levels and renal, hormonal, and hemodynamic responses to peptide infusion","volume":"78","author":"Cody","year":"1986","journal-title":"J\u00a0Clin Invest"},{"issue":"1","key":"10.1016\/j.jacbts.2022.05.010_bib75","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/0167-5273(91)90153-G","article-title":"Attenuated renal excretory response to atrial natriuretic peptide in congestive heart failure in man","volume":"33","author":"Eiskjaer","year":"1991","journal-title":"Int J Cardiol"},{"issue":"3","key":"10.1016\/j.jacbts.2022.05.010_bib76","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1161\/01.CIR.90.3.1210","article-title":"Vasodilatory effects of C-type natriuretic peptide on forearm resistance vessels are distinct from those of atrial natriuretic peptide in chronic heart failure","volume":"90","author":"Nakamura","year":"1994","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.jacbts.2022.05.010_bib77","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1161\/01.ATV.zhq0504.7914","article-title":"Effects of exogenous and endogenous natriuretic peptides on forearm vascular function in chronic heart failure","volume":"24","author":"Schmitt","year":"2004","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"2","key":"10.1016\/j.jacbts.2022.05.010_bib78","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1161\/01.RES.0000232322.06633.d3","article-title":"Novel snake venom ligand dendroaspis natriuretic peptide is selective for natriuretic peptide receptor-A in human heart: downregulation of natriuretic peptide receptor-A in heart failure","volume":"99","author":"Singh","year":"2006","journal-title":"Circ Res"},{"issue":"5","key":"10.1016\/j.jacbts.2022.05.010_bib79","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1139\/y05-163","article-title":"Role of cyclic GMP and calcineurin in homologous and heterologous desensitization of natriuretic peptide receptor-A","volume":"84","author":"Fortin","year":"2006","journal-title":"Can J Physiol Pharmacol"},{"issue":"1","key":"10.1016\/j.jacbts.2022.05.010_bib80","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/0735-1097(88)90371-3","article-title":"Hemodynamic, renal and endocrine effects of atrial natriuretic peptide infusion in severe heart failure","volume":"12","author":"Molina","year":"1988","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"3","key":"10.1016\/j.jacbts.2022.05.010_bib81","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/0002-8703(89)90264-0","article-title":"Hemodynamic, hormonal, and renal effects of atrial natriuretic peptide in untreated congestive cardiac failure","volume":"118","author":"Anand","year":"1989","journal-title":"Am Heart J"},{"issue":"24","key":"10.1016\/j.jacbts.2022.05.010_bib82","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1161\/01.CIR.100.24.2443","article-title":"Renal response to acute neutral endopeptidase inhibition in mild and severe experimental heart failure","volume":"100","author":"Chen","year":"1999","journal-title":"Circulation"},{"issue":"48","key":"10.1016\/j.jacbts.2022.05.010_bib83","doi-asserted-by":"crossref","first-page":"17442","DOI":"10.1073\/pnas.0508782102","article-title":"Quantitative mass spectral evidence for the absence of circulating brain natriuretic peptide (BNP-32) in severe human heart failure","volume":"102","author":"Hawkridge","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1-3","key":"10.1016\/j.jacbts.2022.05.010_bib84","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.regpep.2011.05.005","article-title":"Altered regulation of renal nitric oxide and atrial natriuretic peptide systems in angiotensin II-induced hypertension","volume":"170","author":"Bae","year":"2011","journal-title":"Regul Pept"},{"issue":"2 pt 1","key":"10.1016\/j.jacbts.2022.05.010_bib85","first-page":"E135","article-title":"Interaction of ANP with endothelin on cardiovascular, renal, and endocrine function","volume":"262","author":"Ota","year":"1992","journal-title":"Am J Physiol"},{"issue":"2","key":"10.1016\/j.jacbts.2022.05.010_bib86","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1038\/ki.1991.199","article-title":"Dual mechanism of angiotensin II inhibits ANP-induced mesangial cGMP accumulation","volume":"40","author":"Haneda","year":"1991","journal-title":"Kidney Int"},{"issue":"10","key":"10.1016\/j.jacbts.2022.05.010_bib87","first-page":"800","article-title":"Sacubitril\/valsartan: neprilysin inhibition 5 years after PARADIGM-HF","volume":"8","author":"Docherty","year":"2020","journal-title":"J\u00a0Am Coll Cardiol HF"},{"issue":"19","key":"10.1016\/j.jacbts.2022.05.010_bib88","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1016\/j.jacc.2015.08.878","article-title":"Comparing LCZ696 with enalapril according to baseline risk using the MAGGIC and EMPHASIS-HF risk scores: an analysis of mortality and morbidity in PARADIGM-HF","volume":"66","author":"Simpson","year":"2015","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"4","key":"10.1016\/j.jacbts.2022.05.010_bib89","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1001\/jamacardio.2016.5036","article-title":"Use of risk models to predict death in the next year among individual ambulatory patients with heart failure","volume":"2","author":"Allen","year":"2017","journal-title":"JAMA Cardiol"},{"issue":"10","key":"10.1016\/j.jacbts.2022.05.010_bib90","first-page":"816","article-title":"Efficacy of sacubitril\/valsartan relative to a prior decompensation: the PARADIGM-HF trial","volume":"4","author":"Solomon","year":"2016","journal-title":"J\u00a0Am Coll Cardiol HF"},{"issue":"7","key":"10.1016\/j.jacbts.2022.05.010_bib91","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/j.jacc.2019.07.008","article-title":"Phosphodiesterase-9 inhibition in heart failure: a further opportunity to augment the effects of natriuretic peptides?","volume":"74","author":"McMurray","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"10","key":"10.1016\/j.jacbts.2022.05.010_bib92","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/j.jacc.2006.08.066","article-title":"Acute phosphodiesterase 5 inhibition mimics hemodynamic effects of B-type natriuretic peptide and potentiates B-type natriuretic peptide effects in failing but not normal canine heart","volume":"49","author":"Forfia","year":"2007","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"20","key":"10.1016\/j.jacbts.2022.05.010_bib93","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1056\/NEJMe2115471","article-title":"Drawing boundaries around PARADISE","volume":"385","author":"Stevenson","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.jacbts.2022.05.010_bib94","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/clc.23090","article-title":"Neprilysin levels at the acute phase of ST-elevation myocardial infarction","volume":"42","author":"Bernelin","year":"2019","journal-title":"Clin Cardiol"},{"issue":"3","key":"10.1016\/j.jacbts.2022.05.010_bib95","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1161\/CIRCULATIONAHA.121.054892","article-title":"Effect of neprilysin inhibition on left ventricular remodeling in patients with asymptomatic left ventricular systolic dysfunction late after myocardial infarction","volume":"144","author":"Docherty","year":"2021","journal-title":"Circulation"},{"issue":"13","key":"10.1016\/j.jacbts.2022.05.010_bib96","doi-asserted-by":"crossref","first-page":"4591","DOI":"10.3390\/ijms21134591","article-title":"Early elevation of systemic plasma clusterin after reperfused acute myocardial infarction in a preclinical porcine model of ischemic heart disease","volume":"21","author":"Traxler","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"5","key":"10.1016\/j.jacbts.2022.05.010_bib97","first-page":"H1769","article-title":"Bradykinin metabolism in the postinfarcted rat heart: role of ACE and neutral endopeptidase 24.11","volume":"276","author":"Raut","year":"1999","journal-title":"Am J Physiol"},{"issue":"6","key":"10.1016\/j.jacbts.2022.05.010_bib98","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/S0196-9781(01)00401-6","article-title":"Effects of the vasopeptidase inhibitor omapatrilat on cardiac endogenous kinins in rats with acute myocardial infarction","volume":"22","author":"Blais","year":"2001","journal-title":"Peptides"},{"issue":"1","key":"10.1016\/j.jacbts.2022.05.010_bib99","doi-asserted-by":"crossref","first-page":"5791","DOI":"10.1038\/s41598-019-42113-0","article-title":"Angiotensin receptor neprilysin inhibitor attenuates myocardial remodeling and improves infarct perfusion in experimental heart failure","volume":"9","author":"Pfau","year":"2019","journal-title":"Sci Rep"},{"issue":"9","key":"10.1016\/j.jacbts.2022.05.010_bib100","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1007\/s00125-005-1847-7","article-title":"Neutral endopeptidase 24.11 and dipeptidyl peptidase IV are both mediators of the degradation of glucagon-like peptide 1 in the anaesthetised pig","volume":"48","author":"Plamboeck","year":"2005","journal-title":"Diabetologia"},{"issue":"4","key":"10.1016\/j.jacbts.2022.05.010_bib101","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1007\/s00125-016-4172-4","article-title":"Improved glycaemia in high-fat-fed neprilysin-deficient mice is associated with reduced DPP-4 activity and increased active GLP-1 levels","volume":"60","author":"Willard","year":"2017","journal-title":"Diabetologia"},{"issue":"5","key":"10.1016\/j.jacbts.2022.05.010_bib102","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S2213-8587(17)30087-6","article-title":"Effect of sacubitril\/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial","volume":"5","author":"Seferovic","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"3","key":"10.1016\/j.jacbts.2022.05.010_bib103","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1172\/JCI113120","article-title":"Elevated plasma atrial natriuretic peptide levels in diabetic rats. Potential mediator of hyperfiltration","volume":"80","author":"Ortola","year":"1987","journal-title":"J\u00a0Clin Invest"},{"issue":"2","key":"10.1016\/j.jacbts.2022.05.010_bib104","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1046\/j.1365-2362.1999.00422.x","article-title":"Atrial natriuretic peptide increases albuminuria in type I diabetic patients: evidence for blockade of tubular protein reabsorption","volume":"29","author":"Jacobs","year":"1999","journal-title":"Eur J Clin Invest"},{"issue":"5","key":"10.1016\/j.jacbts.2022.05.010_bib105","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1002\/ejhf.267","article-title":"Combined neprilysin and RAS inhibition for the failing heart: straining the kidney to help the heart?","volume":"17","author":"Ruggenenti","year":"2015","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacbts.2022.05.010_bib106","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.lfs.2019.02.027","article-title":"Concurrent neprilysin inhibition and renin-angiotensin system modulations prevented diabetic nephropathy","volume":"221","author":"Malek","year":"2019","journal-title":"Life Sci"},{"issue":"1","key":"10.1016\/j.jacbts.2022.05.010_bib107","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s12933-019-0847-8","article-title":"The combination of a neprilysin inhibitor (sacubitril) and angiotensin-II receptor blocker (valsartan) attenuates glomerular and tubular injury in the Zucker Obese rat","volume":"18","author":"Habibi","year":"2019","journal-title":"Cardiovasc Diabetol"},{"issue":"6","key":"10.1016\/j.jacbts.2022.05.010_bib108","doi-asserted-by":"crossref","first-page":"F1133","DOI":"10.1152\/ajprenal.00614.2020","article-title":"Sacubitril\/valsartan treatment has differential effects in modulating diabetic kidney disease in db\/db mice and KKAy mice compared with valsartan treatment","volume":"320","author":"Myakala","year":"2021","journal-title":"Am J Physiol Renal Physiol"},{"issue":"7","key":"10.1016\/j.jacbts.2022.05.010_bib109","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S2213-8587(18)30100-1","article-title":"Effect of neprilysin inhibition on renal function in patients with type 2 diabetes and chronic heart failure who are receiving target doses of inhibitors of the renin-angiotensin system: a secondary analysis of the PARADIGM-HF trial","volume":"6","author":"Packer","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"10.1016\/j.jacbts.2022.05.010_bib110","first-page":"489","article-title":"Renal effects and associated outcomes during angiotensin-neprilysin inhibition in heart failure","volume":"6","author":"Damman","year":"2018","journal-title":"J\u00a0Am Coll Cardiol HF"},{"issue":"5","key":"10.1016\/j.jacbts.2022.05.010_bib111","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1002\/ejhf.232","article-title":"Renal effects of the angiotensin receptor neprilysin inhibitor LCZ696 in patients with heart failure and preserved ejection fraction","volume":"17","author":"Voors","year":"2015","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacbts.2022.05.010_bib112","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2021.754499","article-title":"Sacubitril-valsartan, clinical benefits and related mechanisms of action in heart failure with reduced ejection fraction. A review","volume":"8","author":"Pascual-Figal","year":"2021","journal-title":"Front Cardiovasc Med"},{"issue":"12","key":"10.1016\/j.jacbts.2022.05.010_bib113","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1681\/ASN.V5122057","article-title":"Effect of atrial natriuretic peptide on renal and vascular permeability in diabetes mellitus","volume":"5","author":"Zietse","year":"1995","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"10","key":"10.1016\/j.jacbts.2022.05.010_bib114","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1002\/ejhf.603","article-title":"Combined neprilysin and renin-angiotensin system inhibition in heart failure with reduced ejection fraction: a meta-analysis","volume":"18","author":"Solomon","year":"2016","journal-title":"Eur J Heart Fail"},{"issue":"15","key":"10.1016\/j.jacbts.2022.05.010_bib115","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1161\/CIRCULATIONAHA.118.034818","article-title":"Effects of sacubitril\/valsartan versus irbesartan in patients with chronic kidney disease","volume":"138","author":"Haynes","year":"2018","journal-title":"Circulation"},{"issue":"9689","key":"10.1016\/j.jacbts.2022.05.010_bib116","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/S0140-6736(09)61378-7","article-title":"Albuminuria in chronic heart failure: prevalence and prognostic importance","volume":"374","author":"Jackson","year":"2009","journal-title":"Lancet"},{"issue":"23","key":"10.1016\/j.jacbts.2022.05.010_bib117","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1056\/NEJMoa010713","article-title":"A\u00a0randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure","volume":"345","author":"Cohn","year":"2001","journal-title":"N\u00a0Engl J Med"},{"issue":"23","key":"10.1016\/j.jacbts.2022.05.010_bib118","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1056\/NEJM198706043162301","article-title":"Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS)","volume":"316","year":"1987","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.jacbts.2022.05.010_bib119","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.115.002735","article-title":"Factors associated with noncompletion during the run-in period before randomization and influence on the estimated benefit of LCZ696 in the PARADIGM-HF trial","volume":"9","author":"Desai","year":"2016","journal-title":"Circ Heart Fail"},{"issue":"4","key":"10.1016\/j.jacbts.2022.05.010_bib120","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.117.004745","volume":"11","author":"Vardeny","year":"2018","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jacbts.2022.05.010_bib121","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.taap.2017.03.014","article-title":"The effect of angiotensin receptor neprilysin inhibitor, sacubitril\/valsartan, on central nervous system amyloid-beta concentrations and clearance in the cynomolgus monkey","volume":"323","author":"Schoenfeld","year":"2017","journal-title":"Toxicol Appl Pharmacol"},{"issue":"5","key":"10.1016\/j.jacbts.2022.05.010_bib122","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1111\/bcp.12861","article-title":"The effect of LCZ696 (sacubitril\/valsartan) on amyloid-beta concentrations in cerebrospinal fluid in healthy subjects","volume":"81","author":"Langenickel","year":"2016","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.jacbts.2022.05.010_bib123","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1002\/ejhf.687","article-title":"Dementia-related adverse events in PARADIGM-HF and other trials in heart failure with reduced ejection fraction","volume":"19","author":"Cannon","year":"2017","journal-title":"Eur J Heart Fail"},{"issue":"8","key":"10.1016\/j.jacbts.2022.05.010_bib124","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.cardfail.2018.04.010","article-title":"Cognition- and dementia-related adverse effects with sacubitril-valsartan: analysis of the FDA Adverse Event Report System database","volume":"24","author":"Perlman","year":"2018","journal-title":"J\u00a0Card Fail"},{"issue":"2","key":"10.1016\/j.jacbts.2022.05.010_bib125","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0228926","article-title":"In-silico simulated prototype-patients using TPMS technology to study a potential adverse effect of sacubitril and valsartan","volume":"15","author":"Jorba","year":"2020","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.jacbts.2022.05.010_bib126","doi-asserted-by":"crossref","first-page":"e12272","DOI":"10.1111\/1755-5922.12272","article-title":"Pharmacogenomics of angiotensin receptor\/neprilysin inhibitor and\u00a0its\u00a0long-term side effects","volume":"35","author":"Krittanawong","year":"2017","journal-title":"Cardiovasc Ther"},{"issue":"17","key":"10.1016\/j.jacbts.2022.05.010_bib127","doi-asserted-by":"crossref","first-page":"e263","DOI":"10.1016\/j.jacc.2021.12.012","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"79","author":"Heidenreich","year":"2022","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.jacbts.2022.05.010_bib128","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/ejhf.2333","volume":"24","author":"McDonagh","year":"2022","journal-title":"Eur J Heart Fail"}],"container-title":["JACC: Basic to Translational Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2452302X22002212?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2452302X22002212?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T00:25:57Z","timestamp":1762820757000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2452302X22002212"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":128,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["S2452302X22002212"],"URL":"https:\/\/doi.org\/10.1016\/j.jacbts.2022.05.010","relation":{},"ISSN":["2452-302X"],"issn-type":[{"value":"2452-302X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neprilysin Inhibitors in Heart\u00a0Failure","name":"articletitle","label":"Article Title"},{"value":"JACC: Basic to Translational Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacbts.2022.05.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}]}}